BE2014C008I2 - - Google Patents

Download PDF

Info

Publication number
BE2014C008I2
BE2014C008I2 BE2014C008C BE2014C008C BE2014C008I2 BE 2014C008 I2 BE2014C008 I2 BE 2014C008I2 BE 2014C008 C BE2014C008 C BE 2014C008C BE 2014C008 C BE2014C008 C BE 2014C008C BE 2014C008 I2 BE2014C008 I2 BE 2014C008I2
Authority
BE
Belgium
Application number
BE2014C008C
Other languages
French (fr)
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23078354&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BE2014C008(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/US2002/010773 external-priority patent/WO2002080897A1/en
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Publication of BE2014C008I2 publication Critical patent/BE2014C008I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BE2014C008C 2001-04-05 2014-02-13 BE2014C008I2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US28168501P 2001-04-05 2001-04-05
GBGB0123571.2A GB0123571D0 (en) 2001-04-05 2001-10-02 Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis
PCT/US2002/010773 WO2002080897A1 (en) 2001-04-05 2002-04-04 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis

Publications (1)

Publication Number Publication Date
BE2014C008I2 true BE2014C008I2 (en) 2021-02-04

Family

ID=23078354

Family Applications (1)

Application Number Title Priority Date Filing Date
BE2014C008C BE2014C008I2 (en) 2001-04-05 2014-02-13

Country Status (6)

Country Link
US (2) US6794410B2 (en)
BE (1) BE2014C008I2 (en)
CY (1) CY1110446T1 (en)
EC (1) ECSP024244A (en)
GB (1) GB0123571D0 (en)
HN (1) HN2002000110A (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPR245601A0 (en) 2001-01-10 2001-02-01 Silverbrook Research Pty Ltd An apparatus (WSM09)
CA2673398A1 (en) * 2006-12-19 2008-07-03 Merrimack Pharmaceuticals, Inc. Coadministration of alpha-fetoprotein and an immunomodulatory agent to treat multiple sclerosis
EP2277515A1 (en) 2009-07-10 2011-01-26 Sanofi-Aventis Use of the combination of teriflunomide and interferon beta for treating multiple sclerosis
MX336663B (en) * 2009-09-18 2016-01-27 Sanofi Sa (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluormethylphenyl)- amide tablet formulations with improved stability.
EP2314291A1 (en) 2009-10-22 2011-04-27 Sanofi-Aventis Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
CN102655910A (en) 2009-10-22 2012-09-05 赛诺菲-安万特美国有限责任公司 Use of the combination of teriflunomide and glatiramer acetate for treating multiple sclerosis
AR081220A1 (en) 2010-05-26 2012-07-04 Sanofi Aventis Us Llc USE OF TERIFLUNOMIDE FOR THE TREATMENT OF BRAIN ATROPHY
AR081764A1 (en) 2010-05-26 2012-10-17 Sanofi Aventis Us Llc USE OF TERIFLUNOMIDE TO MAINTAIN THE FATIGUE LEVEL OF A PATIENT WHO HAS MULTIPLE SCLEROSIS, MANUFACTURING ARTICLE AND PACKAGING
EP2600861A1 (en) 2010-08-02 2013-06-12 Sanofi-Aventis U.S. LLC Use of teriflunomide for treating multiple sclerosis
JP5820476B2 (en) * 2010-08-24 2015-11-24 アルギアックス ファルマコウティカルス ゲーエムベーハーＡＬＧＩＡＸ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ ＧｍｂＨ New use of leflunomide and malononitrile trilamide
WO2012061060A1 (en) 2010-10-25 2012-05-10 Sanofi-Aventis U.S. Llc Use of teriflunomide for treating brain atrophy
WO2012061062A1 (en) 2010-10-25 2012-05-10 Sanofi-Aventis U.S. Llc Use of teriflunomide for improving motor function
CA2814371C (en) 2010-10-29 2019-03-19 Algiax Pharmaceuticals Gmbh Use of malononitrilamides in neuropathic pain
AR085305A1 (en) 2011-02-24 2013-09-18 Sanofi Aventis Us Llc USE OF TERIFLUNOMIDE FOR THE TREATMENT OF COGNITIVE DETERIORATION
WO2012162339A1 (en) 2011-05-24 2012-11-29 Sanofi-Aventis U.S. Llc Use of teriflunomide for reducing occurrence of relapses requiring healthcare resources
RU2471482C1 (en) * 2011-10-27 2013-01-10 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Composition for treating multiple sclerosis (versions)
RU2493845C1 (en) * 2012-06-07 2013-09-27 Общество с ограниченной ответственностью "ВАЛЕНТА ИНТЕЛЛЕКТ" Composition for treating multiple sclerosis (versions)
EP2762135A1 (en) 2013-02-04 2014-08-06 Sanofi Methods for reducing the risk of an adverse teriflunomide and rosuvastatin interaction in multiple sclerosis patients
JOP20190207A1 (en) * 2017-03-14 2019-09-10 Actelion Pharmaceuticals Ltd Pharmaceutical combination comprising ponesimod

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES448386A1 (en) * 1975-06-05 1978-04-16 Hoechst Ag 5-Methyl-isoxazole-4-carboxylic acid anilides
NL186239B (en) * 1975-06-05 Hoechst Ag PROCESS FOR THE PREPARATION OF A MEDICINAL PRODUCT WITH ANTIFLOGISTICAL AND / OR ANALGETICAL ACTION AND PROCEDURE FOR THE PREPARATION OF A 2-HYDROXYETHYLIDE ENCYANAACETIC ANILIDE SUITABLE FOR USE IN THIS PROCESS.
DE2854439A1 (en) * 1978-12-16 1980-07-03 Hoechst Ag AN ISOXAZOLE DERIVATIVE, METHOD FOR THE PRODUCTION THEREOF, AGENT AND USE THEREOF
US4284784A (en) * 1980-05-22 1981-08-18 Merck & Co., Inc. Process for the preparation of 4-methyl thiazole
DE3534440A1 (en) 1985-09-27 1987-04-02 Hoechst Ag DRUGS AGAINST CHRONIC GRAFT VERSUS HOST DISEASES AND AUTO AUTO DISEASES, IN PARTICULAR SYSTEMIC LUPUS ERYTHEMATODES
US5268382A (en) * 1985-09-27 1993-12-07 Hoechst Aktiengesellschaft Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus
US4965278A (en) * 1989-04-21 1990-10-23 Warner-Lambert Company 7-(substituted)amino)-8-((substituted)carbonyl)-methylamino)-1-oxaspiro[4,5]decanes as diuretics antiiflammatory, and cerebrovascular agents
US6133301A (en) 1991-08-22 2000-10-17 Aventis Pharma Deutschland Gmbh Pharmaceuticals for the treatment of rejection reactions in organ transplantations
IT1254519B (en) 1992-03-16 1995-09-25 Chiesi Farma Spa ASSOCIATIONS OF ANTIVIRAL COMPOUNDS
WO1994024095A1 (en) 1993-04-16 1994-10-27 Abbott Laboratories Immunosuppressive agents
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
DE19534649A1 (en) 1995-09-19 1997-03-20 Hoechst Ag 2-cyano-3-mercaptocrotonic acid amides
DE19547648A1 (en) 1995-12-20 1997-06-26 Hoechst Ag Preparation containing high density lipoproteins and crotonic acid amide derivatives
DE19610955A1 (en) 1996-03-20 1997-09-25 Hoechst Ag Combination preparation containing 5-methylisoxazole-4-carboxylic acid- (4-trifluoromethyl) -anilide and N- (4-trifluoromethylphenyl) -2-cyano-3-hydroxycrotonic acid amide
US6011051A (en) 1996-07-31 2000-01-04 Hoechst Aktiengesellschaft Use of isoxazole and crotonamide derivatives for the modulation of apoptosis
US5981536A (en) 1996-07-31 1999-11-09 Hoechst Aktiengesellschaft Use of xanthine derivatives for the modulation of apoptosis
US5856330A (en) 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
PT903345E (en) 1997-08-08 2001-01-31 Aventis Pharma Gmbh CRYSTALLINE FORM OF N- (4-TRIFLUOROMETHYLPHENYL) -5-METHYL ISOXAZOLE-4-CARBOXAMIDE
DE19857009A1 (en) 1998-12-10 2000-06-15 Aventis Pharma Gmbh Preparation with improved therapeutic range, containing nucleotide synthesis inhibitors
CZ20023024A3 (en) * 2000-02-15 2003-05-14 Teva Pharmaceutical Industries Ltd. Leflunomide synthesis process

Also Published As

Publication number Publication date
US20020177623A1 (en) 2002-11-28
US20030223960A1 (en) 2003-12-04
US6794410B2 (en) 2004-09-21
HN2002000110A (en) 2002-07-04
ECSP024244A (en) 2002-08-01
GB0123571D0 (en) 2001-11-21
CY1110446T1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
BE2022C531I2 (en)
BE2022C502I2 (en)
BE2022C547I2 (en)
BE2017C059I2 (en)
BE2017C056I2 (en)
BE2017C051I2 (en)
BE2017C032I2 (en)
BE2016C051I2 (en)
BE2015C046I2 (en)
BE2017C050I2 (en)
BE2014C052I2 (en)
BE2014C036I2 (en)
JP2002013743A5 (en)
BRPI0209186B1 (en)
BRPI0204884A2 (en)
BE2014C008I2 (en)
BE2016C021I2 (en)
JP2001238249A5 (en)
JP2002218871A5 (en)
BRPI0210463A2 (en)
JP2002025907A5 (en)
JP2002113841A5 (en)
JP2002244009A5 (en)
JP2002050634A5 (en)
JP2002108313A5 (en)